1) At a Glance – The Fall of a Pharma Darling?
Cohance Lifesciences is currently trading at ₹313 with a market cap of ₹11,984 Cr. In the last 3 months alone, the stock has collapsed 44.7%, and over 1 year, it’s down a brutal 71.9%. That’s not correction. That’s emotional damage.
Q3 FY26 numbers? Sales at ₹545 Cr, down 19.5% YoY. PAT at ₹29 Cr, down 73.8% YoY. Operating margins have compressed to 18% from 35% a year ago. Stock P/E sits at 39.8 while industry median is around 27.9. ROCE at 14.9%, ROE at 12.7%.
And then came the cherry on top — USFDA Warning Letter at the Nacharam formulation facility. Management says US revenue from that unit is <2% of FY25 revenue. But the market heard only one word: “Warning.”
Is this a one-year timing issue? Or is the CDMO growth story showing cracks?
Let’s open the case file.
2) Introduction – A CDMO with a Hangover
Cohance is a Hyderabad-based CDMO player operating in the high-end NCE space. Translation? They help pharma innovators develop and manufacture new chemical entities from lab to commercial scale.
In theory, this is premium business. Sticky clients. Long pipelines. High margins.
In practice? FY26 has turned into a transition year. Management has openly admitted that revenue will decline early-to-mid double digits this year.
Why?
• ₹260 Cr destocking from two large commercial products
• ₹55 Cr shipment deferral due to Nacharam warning letter
• Slower commercialization of Phase-3 molecules
• Biotech funding slowdown affecting subsidiaries
And suddenly the stock went from growth darling to “what just happened?” category.
But before we panic — let’s understand what they actually do.
3) Business Model – WTF Do They Even Do?
Cohance operates across three verticals:
1️ Pharma CDMO (72% revenue in H1 FY25)
This is the crown jewel.
They do:
• Custom synthesis
• Process R&D
• Scale-up
• Commercial manufacturing
Currently:
• 12 commercial patented molecules
• 7 Phase-3 molecules
• 9 Phase-3 supported overall
Management expects 4 molecules to move to commercialization in coming fiscal year.
But here’s the catch — commercialization ramp-up has been slower than expected.
Why? Innovators are delaying launches, recalibrating inventory, and managing lifecycle risks.
CDMO is not FMCG. One molecule hiccup = revenue drama.
2️ Specialty Chemicals (6% in H1 FY25)
This segment fell 76% YoY in H1 FY25 due to macro challenges.
But 9M FY26 revenue is up 32% YoY
